0001209191-23-014442.txt : 20230302 0001209191-23-014442.hdr.sgml : 20230302 20230302073831 ACCESSION NUMBER: 0001209191-23-014442 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stark David Matthew CENTRAL INDEX KEY: 0001722360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 23696439 MAIL ADDRESS: STREET 1: 5 BASEL STREET, P.O. BOX 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 4951033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 BUSINESS PHONE: 9729267267 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-28 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001722360 Stark David Matthew C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL 0 1 0 0 Exec. VP Chief Legal Officer Ordinary Shares 2023-02-28 4 M 0 18430 A 21404.39 D Ordinary Shares 2023-02-28 4 S 0 18430 9.8866 D 2974.39 D Ordinary Shares 2023-02-28 4 M 0 44953 A 47927.39 D Ordinary Shares 2023-02-28 4 S 0 44953 9.8866 D 2974.39 D Restricted Share Units 2023-02-28 4 M 0 18430 0.00 D Ordinary Shares 18430 18430 D Restricted Share Units 2023-02-28 4 M 0 44953 0.00 D Ordinary Shares 44953 0 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 18,430 vesting on February 28, 2024. Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. /s/ Dov Bergwerk as attorney-in-fact for David M. Stark 2023-03-02